J. McEvoy

发表

The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.

J. Lieberman, J. Cañive, T. Stroup, 2003, Schizophrenia bulletin.

Assessing Clinical and Functional Outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (catie) Schizophrenia Trial Send Reprint Requests to Clinical Outcome Measures: Primary Outcome Clinical and Functional Outcomes Table 1. Catie Schizophrenia Trial Centers' Clinical and Func

T. Stroup, J. McEvoy, M. Swartz, 2022 .

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

J. Lieberman, B. Lebowitz, S. Davis, 2005, The New England journal of medicine.

Time-lapse mapping of cortical changes in schizophrenia with different treatments.

J. Lieberman, G. Bartzokis, A. Toga, 2009, Cerebral cortex.

Source-monitoring deficits for self-generated stimuli in schizophrenia: multinomial modeling of data from three sources

J. McEvoy, U. Bayen, R. Keefe, 2002, Schizophrenia Research.

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

Michael F. Green, Philip D. Harvey, J. Lieberman, 2007, Archives of general psychiatry.

Overt Aggression and Psychotic Symptoms in Patients With Schizophrenia Treated With Clozapine, Olanzapine, Risperidone, or Haloperidol

J. Lieberman, P. Czobor, J. McEvoy, 2004, Journal of clinical psychopharmacology.

Neurocognitive correlates of the COMT Val158Met polymorphism in chronic schizophrenia

J. Lieberman, A. Malhotra, P. Czobor, 2002, Biological Psychiatry.

Spatial and Temporal Mapping of De Novo Mutations in Schizophrenia to a Fetal Prefrontal Cortical Network

L. Siever, B. Turetsky, T. Walsh, 2013, Cell.

Antipsychotic drug effects on brain morphology in first-episode psychosis.

J. Lieberman, R. Kahn, R. Gur, 2005, Archives of general psychiatry.

Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.

J. Lieberman, J. Sweeney, H. Gu, 2007, The American journal of psychiatry.

What CATIE found: results from the schizophrenia trial.

J. Lieberman, S. Davis, J. Hsiao, 2008, Psychiatric services.

Baseline Neurocognitive Deficits in the CATIE Schizophrenia Trial

Michael F. Green, Philip D. Harvey, J. Lieberman, 2006, Neuropsychopharmacology.

A collaborative study of a new antidepressant, viloxazine, in neurotic and endogenous depressives.

J. McEvoy, W. Wilson, W. Guy, 1982, International pharmacopsychiatry.

A Guide to the Management of Clozapine-Related Tolerability and Safety Concerns.

J. McEvoy, L. Citrome, Stephen R Saklad, 2016, Clinical schizophrenia & related psychoses.

Long-term effect of aripiprazole lauroxil on health-related quality of life in patients with schizophrenia

P. Weiden, J. McEvoy, Xiaowu Sun, 2021, BMC Psychiatry.

FC09.05 Clozapine, olanzapine, risperidone, and haloperidol in refractory schizophrenia

P. Czobor, J. McEvoy, J. Volavka, 2000, European Psychiatry.

Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.

J. Lieberman, P. Czobor, J. McEvoy, 2001, Psychiatric services.

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

J. Lieberman, P. Czobor, J. McEvoy, 2002, The American journal of psychiatry.

Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.

J. Lieberman, P. Czobor, J. McEvoy, 2004, The Journal of clinical psychiatry.

Guide to the Management of Clozapine-Related Tolerability and Safety Concerns.

J. McEvoy, L. Citrome, Stephen R Saklad, 2016, Clinical schizophrenia & related psychoses.

Brexpiprazole for the Treatment of Schizophrenia: A Review of this Novel Serotonin-Dopamine Activity Modulator.

J. McEvoy, L. Citrome, 2016, Clinical schizophrenia & related psychoses.

Clozapine for self-injurious behavior in individuals with borderline personality disorder

J. McEvoy, Theodore Zarzar, Theodore R Zarzar, 2013, Therapeutic advances in psychopharmacology.

Predictors of therapeutic response to haloperidol in acute schizophrenia.

J. McEvoy, W. Wilson, N. Schooler, 1991, Psychopharmacology bulletin.

Differences in the Nature of Relapse and Subsequent Inpatient Course between Medication‐Compliant and Noncompliant Schizophrenic Patients

J. McEvoy, G. Hogarty, A. Howe, 1984, The Journal of nervous and mental disease.

A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia

J. McEvoy, S. Targum, D. V. van Kammen, 1996, Psychopharmacology.

Much ado about small differences

J. McEvoy, 2009, World psychiatry : official journal of the World Psychiatric Association.

Comparative effectiveness of antipsychotic drugs in schizophrenia

J. Lieberman, S. Stroup, T. Stroup, 2000, Dialogues in clinical neuroscience.

Clozapine-induced electroencephalogram changes as a function of clozapine serum levels

J. McEvoy, R. Weiner, O. Freudenreich, 1997, Biological Psychiatry.

Background Althoughpeoplewith schizophrenia display impaired abilities for consent, it is notknownhowmuch impairmentconstitutes incapacity. Aims To assess amethod for determiningthecategoricalcapacitystatus of potentialparticipants in schizophrenia research. Method Expert-judgement validation of cap

D. Jeste, D. Goff, T. Stroup, 2007 .

Antipsychotic medications for schizophrenia--reply.

R. Hamer, T. Stroup, J. McEvoy, 2014, JAMA.

Principal Components of Heritability From Neurocognitive Domains Differ Between Families With Schizophrenia and Control Subjects

L. Klei, B. Devlin, R. Gur, 2012, Schizophrenia bulletin.

Identification of a naturally occurring 21 bp deletion in alpha 2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment.

J. Lieberman, J. Vincent, P. Czobor, 2005, Pharmacological research.

Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.

J. Lieberman, P. Czobor, J. McEvoy, 2002, The Journal of clinical psychiatry.

Impaired insight in schizophrenia: impact on patient-reported and physician-reported outcome measures in a randomized controlled trial

P. Weiden, J. McEvoy, Xiaowu Sun, 2022, BMC Psychiatry.

A double-blind comparison of abecarnil and diazepam in the treatment of uncomplicated alcohol withdrawal

J. McEvoy, H. Kranzler, R. Anton, 1997, Psychopharmacology.

Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.

J. Lieberman, S. Davis, R. Rosenheck, 2011, The Journal of clinical psychiatry.

A Genome-Wide Investigation of SNPs and CNVs in Schizophrenia

David B. Goldstein, Lefkos T. Middleton, Hans-Jürgen Möller, 2009, PLoS genetics.

Reliabilities and intercorrelations of reported and objective measures of smoking in patients with schizophrenia

E. Levin, J. McEvoy, W. Wilson, 2003, Schizophrenia Research.

Insight and the Clinical Outcome of Schizopheric Patients

J. McEvoy, P. Appelbaum, L. Roth, 1989, The Journal of nervous and mental disease.

Pharmacotherapy of impaired affect in recovering schizophrenic patients.

J. McEvoy, G. Hogarty, R. Ulrich, 1995, Archives of general psychiatry.

The importance of nicotinic acetylcholine receptors in schizophrenia, bipolar disorder and Tourette's syndrome.

J. McEvoy, T. Allen, J. Mcevoy, 2002, Current drug targets. CNS and neurological disorders.

Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.

J. Lieberman, H. Gu, R. Hamer, 2008, The Journal of clinical psychiatry.

Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients.

P. Keck, R. Hirschfeld, J. McEvoy, 1999, The Journal of clinical psychiatry.

Inflammatory Markers in Schizophrenia: Comparing Antipsychotic Effects in Phase 1 of the CATIE Schizophrenia Trial

J. McEvoy, Jonathan M. Meyer, J. Mcevoy, 2013 .

Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.

J. McEvoy, S. Factor, W. Ondo, 2017, The lancet. Psychiatry.

Placebo controls in clinical trials: concerns about use in relapse prevention studies in schizophrenia

R. Emsley, S. Galderisi, J. McEvoy, 2016, British Medical Journal.

25-Hydroxyvitamin D and metabolic-related laboratory values in women with schizophrenia and hyperprolactinemia.

Megan M. Powell, D. Kelly, H. Wehring, 2022, Journal of psychiatric research.

Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol

J. Lieberman, R. Kahn, R. Gur, 2005, British Journal of Psychiatry.

Smoking in first-episode patients with schizophrenia.

J. McEvoy, S. Brown, J. Mcevoy, 1999, The American journal of psychiatry.

Viloxazine in the Treatment of Depressive Neurosis: A Controlled Clinical Study with Doxepin and Placebo

J. McEvoy, W. R. Stewart, W. Wilson, 1980, British Journal of Psychiatry.

The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update.

Alexander L. Miller, S. Stroup, M. Crismon, 2007, The Journal of clinical psychiatry.

Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study.

J. McEvoy, G. Hogarty, R. Ulrich, 1988, Archives of general psychiatry.

Early Recognition and Treatment of Tardive Dyskinesia in Patients With Mood Disorders and Schizophrenia.

J. McEvoy, Daniel E. Kremens, J. Mcevoy, 2020, The Journal of clinical psychiatry.

Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges.

J. McEvoy, M. McGee, T. Cooper, 1996, The American journal of psychiatry.

A pilot study of a structured interview addressing sexual function in men with schizophrenia

J. McEvoy, J. Ritchie, M. Burke, 1994, Biological Psychiatry.

Heterogeneity of Treatment Effects of Long-Acting Injectable Antipsychotic Medications.

R. Rosenheck, T. Stroup, J. McEvoy, 2018, The Journal of clinical psychiatry.

Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.

T. Stroup, J. McEvoy, S. Essock, 2012, The Journal of clinical psychiatry.

Drugs of the psychopharmacological revolution in clinical psychiatry.

J. Lieberman, S. Stroup, J. McEvoy, 2000, Psychiatric services.

Asenapine once daily versus twice daily: impact on patient acceptance in a randomized, open-label, 14-day clinical trial.

R. Hamer, J. McEvoy, Xiaowei Sun, 2015, The Journal of clinical psychiatry.

Measuring chronic schizophrenic patients attitudes toward their illness and treatment.

J. McEvoy, W. Wilson, W. Guy, 1981, Hospital & community psychiatry.

The importance of early treatment of schizophrenia.

J. McEvoy, J. Mcevoy, 2007, Behavioral healthcare.

Dosing Issues: Target Symptoms and Dose Response

J. McEvoy, 1995 .

Adjunctive Minocycline in Clozapine-Treated Patients with Schizophrenia: Analyzing the Effects of Minocycline on Clozapine Plasma Levels

D. Kelly, H. Wehring, S. Feldman, 2018, Psychiatric Quarterly.

Use of Clozapine in Schizophrenia.

J. McEvoy, J. Mcevoy, 2016, JAMA psychiatry.

The neuroleptic threshold as a marker of minimum effective neuroleptic dose.

J. McEvoy, J. Mcevoy, 1986, Comprehensive psychiatry.

Insight in Schizophrenia. Its Relationship to Acute Psychopathology

J. McEvoy, P. Appelbaum, L. Roth, 1989, The Journal of nervous and mental disease.

Negative symptom and cognitive deficit treatment response in schizophrenia

J. McEvoy, R. Keefe, J. Mcevoy, 2001 .

Aggression as a personality trait in Egernia whitii mechanisms and outcomes

J. McEvoy, J. McEvoy, J. Mcevoy, 2013 .

Results of phase 3 of the CATIE schizophrenia trial

Alexander L. Miller, J. Lieberman, S. Davis, 2009, Schizophrenia Research.

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.

J. Lieberman, S. Davis, J. Hsiao, 2006, The American journal of psychiatry.

Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia

Richard A. Van Dorn, J. Lieberman, H. Wagner, 2008, British Journal of Psychiatry.

The costs of schizophrenia.

J. McEvoy, J. Mcevoy, 2007, The Journal of clinical psychiatry.

Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.

J. Lieberman, S. Davis, J. Hsiao, 2006, The American journal of psychiatry.

The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: Clinical comparison of subgroups with and without the metabolic syndrome

J. Lieberman, S. Davis, D. Goff, 2005, Schizophrenia Research.

Long-term efficacy and safety of atypical and conventional antipsychotic drugs in first episode schizophrenia

J. Lieberman, R. Gur, M. Tohen, 2003, Schizophrenia Research.

Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III

J. Lieberman, S. Davis, D. Goff, 2005, Schizophrenia Research.

The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.

Alexander L. Miller, S. Stroup, A. Rush, 2004, The Journal of clinical psychiatry.

Cognitive Effects of Neonatal Hippocampal Lesions in a Rat Model of Schizophrenia

Edward D. Levin, R. Andrew Chambers, E. Levin, 1996, Neuropsychopharmacology.

Current standard treatments

J. McEvoy, J. Mcevoy, 2012 .

A national study of violent behavior in persons with schizophrenia.

J. Lieberman, H. Wagner, R. Rosenheck, 2006, Archives of general psychiatry.

Barriers to employment for people with schizophrenia.

Marvin Swartz, Jeffrey Lieberman, Diana Perkins, 2006, The American journal of psychiatry.

A Randomized Clinical Trial of MK-0777 for the Treatment of Cognitive Impairments in People with Schizophrenia

Daniel C. Javitt, Jeffrey A. Lieberman, John G. Csernansky, 2011, Biological Psychiatry.

Smoking and therapeutic response to clozapine in patients with schizophrenia

J. McEvoy, W. Wilson, O. Freudenreich, 1999, Biological Psychiatry.

Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1

J. Lieberman, S. Davis, R. Rosenheck, 2008, Schizophrenia Research.

Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode

Jacqueline L Johnson, J. Lieberman, R. Kahn, 2006, Schizophrenia Research.

Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose.

S. Steingard, J. McEvoy, G. Hogarty, 1991, Archives of general psychiatry.

Insight in first-episode psychosis

J. Lieberman, M. Tohen, R. Hamer, 2006, Psychological Medicine.

Striatal dopamine D2/D3 receptor availability in male smokers

J. McEvoy, P. Chen, I. Lee, 2006, Psychiatry Research: Neuroimaging.

A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls

J. Lieberman, R. D'Agostino, S. Davis, 2005, Schizophrenia Research.

Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis

D. Ge, A. Need, D. Goldstein, 2009, European Journal of Human Genetics.

Lipidomics Reveals Early Metabolic Changes in Subjects with Schizophrenia: Effects of Atypical Antipsychotics

Henry A. Nasrallah, Matcheri S. Keshavan, Rima Kaddurah-Daouk, 2013, PloS one.

Metabolomic mapping of atypical antipsychotic effects in schizophrenia

K. Krishnan, P. Doraiswamy, R. Kaddurah-Daouk, 2007, Molecular Psychiatry.

Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.

J. Lieberman, H. Gu, R. Hamer, 2007, The American journal of psychiatry.

Antipsychotic-Induced Weight Gain and Therapeutic Response: A Differential Association

J. Lieberman, P. Czobor, J. McEvoy, 2002, Journal of clinical psychopharmacology.

Aripiprazole: pharmacology, efficacy, safety and tolerability

J. McEvoy, Warren A. Kinghorn, J. Mcevoy, 2005, Expert review of neurotherapeutics.

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.

J. Lieberman, P. Czobor, J. McEvoy, 2003, The American journal of psychiatry.

Why must some schizophrenic patients be involuntarily committed? The role of insight.

J. McEvoy, J. Geller, S. Freter, 1989, Comprehensive psychiatry.

Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs

Peilin Jia, Zhongming Zhao, Patrick F. Sullivan, 2010, Molecular Psychiatry.

The relationship between insight in psychosis and compliance with medications.

J. McEvoy, J. Mcevoy, 1998 .

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.

J. Lieberman, R. Kahn, R. Gur, 2003, The American journal of psychiatry.

Adjunct Aripiprazole Reduces Prolactin and Prolactin-Related Adverse Effects in Premenopausal Women With Psychosis: Results From the DAAMSEL Clinical Trial

Megan M. Powell, F. Dickerson, D. Kelly, 2018, Journal of clinical psychopharmacology.

Measuring outcome priorities and preferences in people with schizophrenia

Marvin Swartz, Jeffrey Lieberman, Diana Perkins, 2005, British Journal of Psychiatry.

Clinical correlates of tardive dyskinesia in schizophrenia: Baseline data from the CATIE schizophrenia trial

J. Lieberman, S. Davis, R. Rosenheck, 2005, Schizophrenia Research.

The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia

J. Lieberman, W. Honer, P. Czobor, 2005, Neuroscience Letters.

Metabolic profiles of second-generation antipsychotics in early psychosis: Findings from the CAFE study

J. Lieberman, R. Hamer, J. McEvoy, 2009, Schizophrenia Research.

Olanzapine and haloperidol in first episode psychosis: Two-year data

J. Lieberman, R. Kahn, R. Gur, 2006, Schizophrenia Research.

Genome-Wide Pharmacogenomic Study of Neurocognition As an Indicator of Antipsychotic Treatment Response in Schizophrenia

Jeffrey A Lieberman, Patrick F Sullivan, Robert E Vann, 2011, Neuropsychopharmacology.

Prioritizing Harm

J. McEvoy, E. Buchanan, P. Buckley, 2017, Journal of personality assessment.

Hospitalized schizophrenic patient views about seclusion.

J. McEvoy, H. Koral, N. Schneider, 1989, The Journal of clinical psychiatry.

Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study

J. Lieberman, S. Davis, J. Hsiao, 2008, Schizophrenia Research.

Mecamylamine increases cigarette smoking in psychiatric patients.

J. McEvoy, W. Wilson, C. Marx, 2000, Journal of clinical psychopharmacology.

A single assessment with the Brief Adherence Rating Scale (BARS) discriminates responders to long-acting injectable antipsychotic treatment in patients with schizophrenia

R. Rosenheck, T. Stroup, J. McEvoy, 2020, Schizophrenia Research.

Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective Disorder

Jeffrey A. Lieberman, Brian Sheitman, Leslie Citrome, 2002 .

A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).

J. Lieberman, R. Rosenheck, T. Stroup, 2011, The American journal of psychiatry.

Exome sequencing followed by large-scale genotyping suggests a limited role for moderately rare risk factors of strong effect in schizophrenia.

Jari Tiihonen, Herbert Y Meltzer, David B Goldstein, 2012, American journal of human genetics.

Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia

J. McEvoy, P. Llorca, C. Correll, 2021, CNS Drugs.

A Modified Delphi Consensus Study of the Screening, Diagnosis, and Treatment of Tardive Dyskinesia.

R. McIntyre, J. McEvoy, T. Ketter, 2020, The Journal of clinical psychiatry.

Effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia

M. Kosinski, J. McEvoy, J. Bjorner, 2019, Quality of Life Research.

Risks versus benefits of different types of long-acting injectable antipsychotics.

J. McEvoy, J. Mcevoy, 2006, The Journal of clinical psychiatry.

What CATIE Found: Results From the Schizophrenia Trial

J. Lieberman, S. Davis, J. Hsiao, 2008 .

Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study.

J. McEvoy, L. Citrome, J. Cucchiaro, 2013, The Journal of clinical psychiatry.

Monitoring of clozapine blood levels in the real world.

J. McEvoy, T. Cooper, O. Freudenreich, 1996, Journal of clinical psychopharmacology.

Longitudinal study of inflammatory markers and psychopathology in schizophrenia

J. McEvoy, B. Miller, T. Feng, 2020, Schizophrenia Research.

Inflammation, substance use, psychopathology, and cognition in phase 1 of the clinical antipsychotic trials of intervention effectiveness study

J. McEvoy, P. Buckley, B. Miller, 2017, Schizophrenia Research.

Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline

J. Lieberman, S. Davis, D. Goff, 2006, Schizophrenia Research.

Introduction: An Overview of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Study

J. McEvoy, 2006, CNS Spectrums.

Effectiveness of switching from antipsychotic polypharmacy to monotherapy.

Alexander L. Miller, J. Csernansky, T. Stroup, 2011, The American journal of psychiatry.

Second-generation antipsychotics: reviewing the cost–effectiveness component of the CATIE trial

J. Lieberman, S. Davis, J. Hsiao, 2007, Expert review of pharmacoeconomics & outcomes research.

Haase hermeneutics, or, the exegesis of the neuroleptic threshold.

J. McEvoy, L. Kamaraju, L. Nelson, 1992, Journal of Clinical Psychopharmacology.

Optimizing outcome with antipsychotic treatment in first-episode schizophrenia: balancing efficacy and side effects.

J. McEvoy, O. Freudenreich, J. Mcevoy, 2012, Clinical schizophrenia & related psychoses.

ACADEMIC HIGHLIGHTS

J. McEvoy, S. Marder, D. Mamo, 2008 .

A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future

P. Weiden, J. McEvoy, M. Todtenkopf, 2019, Neuropsychiatric disease and treatment.

NDT_A_209284 2559..2569

P. Weiden, J. McEvoy, M. Todtenkopf, 2019 .

Interrelationships of psychiatric symptom severity, medical comorbidity, and functioning in schizophrenia.

J. Lieberman, R. Rosenheck, J. McEvoy, 2006, Psychiatric services.

The impact of obesity on health care costs among persons with schizophrenia.

J. Lieberman, S. Davis, R. Rosenheck, 2009, General hospital psychiatry.

Nicotine–Haloperidol Interactions and Cognitive Performance in Schizophrenics

E. Levin, J. McEvoy, W. Wilson, 1996, Neuropsychopharmacology.

Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study

D. Goldstein, P. Sullivan, M. Weale, 2008, Genetics in Medicine.

Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.

Alexander L. Miller, J. Lieberman, S. Davis, 2007, The American journal of psychiatry.

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.

J. Lieberman, S. Davis, J. Hsiao, 2006, The American journal of psychiatry.

Substance abuse (including nicotine) in schizophrenic patients

J. McEvoy, T. Allen, J. Mcevoy, 2003 .

Employment Outcomes in a Randomized Trial of Second-Generation Antipsychotics and Perphenazine in the Treatment of Individuals with Schizophrenia

J. Lieberman, S. Davis, R. Rosenheck, 2008, The Journal of Behavioral Health Services & Research.

Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.

J. Lieberman, S. Davis, J. Hsiao, 2007, The American journal of psychiatry.

Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic

J. Lieberman, S. Davis, J. Hsiao, 2006 .

Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia

J. Lauriello, J. McEvoy, R. Lasser, 2005, Schizophrenia Research.

A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.

J. McEvoy, D. Daniel, R. Mcquade, 2007, Journal of psychiatric research.

Haloperidol increases smoking in patients with schizophrenia

E. Levin, J. McEvoy, O. Freudenreich, 1995, Psychopharmacology.

Clozapine decreases smoking in patients with chronic schizophrenia

E. Levin, J. McEvoy, M. McGee, 1995, Biological Psychiatry.

The RAISE Connection Program: Psychopharmacological Treatment of People With a First Episode of Schizophrenia.

Thomas E. Smith, L. Dixon, R. Buchanan, 2016, Psychiatric services.

Substance Use in Persons With Schizophrenia: Baseline Prevalence and Correlates From the NIMH CATIE Study

Richard A. Van Dorn, J. Lieberman, H. Wagner, 2006, The Journal of nervous and mental disease.

Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia.

J. Lieberman, S. Stroup, R. Rosenheck, 2009, Schizophrenia bulletin.

Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia

S. Rozen, M. Keshavan, R. Krishnan, 2010, Molecular Psychiatry.

Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia.

J. Lieberman, S. Davis, R. Rosenheck, 2011, The Journal of clinical psychiatry.

Correction: A Genome-Wide Investigation of SNPs and CNVs in Schizophrenia

D. Rujescu, P. Muglia, C. Francks, 2009, PLoS Genetics.

Negative symptom and cognitive deficit treatment response in schizophrenia

J. McEvoy, R. Keefe, 2001 .

A double-blind crossover comparison of antiparkinson drug therapy: amantadine versus anticholinergics in 90 normal volunteers, with an emphasis on differential effects on memory function.

J. McEvoy, 1987, The Journal of clinical psychiatry.

Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia

J. Lieberman, J. Sweeney, H. Gu, 2008, Journal of the International Neuropsychological Society.

Persistent infection with neurotropic herpes viruses and cognitive impairment

L. Klei, B. Devlin, R. Yolken, 2012, Psychological Medicine.

Expert Consensus Treatment Guidelines for Schizophrenia: A Guide for Patients and Families

P. Weiden, J. McEvoy, A. Frances, 1999 .

Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms

D. Kelly, H. Wehring, S. Feldman, 2015, Journal of clinical psychopharmacology.

Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia

Michael F. Green, D. Javitt, D. Goff, 2012, Schizophrenia Research.

Meta-analysis of clozapine and insomnia in schizophrenia

J. McEvoy, B. Miller, W. McCall, 2023, Schizophrenia Research.

Insomnia, Suicidal Ideation, and Suicide Attempts in the Clinical Antipsychotic Trials of Intervention Effectiveness.

J. McEvoy, B. Miller, W. McCall, 2021, The Journal of clinical psychiatry.

Project among African-Americans to explore risks for schizophrenia (PAARTNERS): Recruitment and assessment methods

B. Devlin, J. Ragland, R. Gur, 2006, Schizophrenia Research.

The Clinical Use of Anticholinergic Drugs As Treatment for Extrapyramidal Side Effects of Neuroleptic Drugs

J. McEvoy, J. Mcevoy, 1983, Journal of clinical psychopharmacology.

Palinacousis after closed-head injury in a patient with schizophrenia.

J. McEvoy, O. Freudenreich, 1996, Journal of Clinical Psychopharmacology.

Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder.

J. Lieberman, P. Czobor, J. McEvoy, 2005, Journal of psychiatric research.

Effects of Davunetide on N-acetylaspartate and Choline in Dorsolateral Prefrontal Cortex in Patients with Schizophrenia

J. Lieberman, D. Javitt, D. Barch, 2013, Neuropsychopharmacology.

Suggestive association between the C825T polymorphism of the G-protein β3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia

J. Lieberman, P. Czobor, J. McEvoy, 2005, European Neuropsychopharmacology.

Heritability of functioning in families with schizophrenia in relation to neurocognition

B. Devlin, R. Gur, M. Calkins, 2012, Schizophrenia Research.

Inflammatory Markers in Schizophrenia: Comparing Antipsychotic Effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study

J. Lieberman, S. Davis, J. Hsiao, 2009, Biological Psychiatry.

Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study

P. Weiden, J. McEvoy, C. Correll, 2013, CNS Spectrums.

Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia

S. Stroup, R. Rosenheck, Haiqun Lin, 2015, The Journal of nervous and mental disease.

Substance use and schizophrenia: Adverse correlates in the CATIE study sample

R. Rosenheck, T. Stroup, J. McEvoy, 2011, Schizophrenia Research.

Linkage analysis of schizophrenia in African-American families

L. Klei, B. Devlin, R. Gur, 2009, Schizophrenia Research.

Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: Results from a randomized controlled trial

R. Hamer, T. Stroup, J. McEvoy, 2013, Schizophrenia Research.

Determining when impairment constitutes incapacity for informed consent in schizophrenia research.

D. Jeste, D. Goff, T. Stroup, 2007, The British journal of psychiatry : the journal of mental science.

Source monitoring improvement in patients with schizophrenia receiving antipsychotic medications

Margaret P. Poe, J. McEvoy, R. Keefe, 2003, Psychopharmacology.

Functional outcomes in schizophrenia.

J. McEvoy, J. Mcevoy, 2008, The Journal of clinical psychiatry.

The characteristics of cognitive neuroscience tests in a schizophrenia cognition clinical trial: Psychometric properties and correlations with standard measures

Michael F. Green, Charlotte A. Chun, J. Lieberman, 2019, Schizophrenia Research: Cognition.

Longitudinal consent-related abilities among research participants with schizophrenia: Results from the CATIE study

J. Lieberman, H. Gu, T. Stroup, 2011, Schizophrenia Research.

Evaluation of HLA polymorphisms in relation to schizophrenia risk and infectious exposure.

L. Klei, B. Devlin, R. Yolken, 2012, Schizophrenia bulletin.

Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial.

R. Rosenheck, R. Hamer, T. Stroup, 2014, JAMA.

Common sense, insight, and neuropsychological test performance in schizophrenia patients.

J. McEvoy, W. Wilson, M. Hartman, 1996, Schizophrenia bulletin.

ADJUNCTIVE MINOCYCLINE IN CLOZAPINE TREATED SCHIZOPHRENIA PATIENTS

D. Kelly, H. Wehring, S. Feldman, 2014, Schizophrenia Research.

Efficacy of risperidone on positive features of schizophrenia.

J. McEvoy, 1994, Journal of Clinical Psychiatry.

Impaired plasmalogens in patients with schizophrenia

Henry A. Nasrallah, Vishwajit L. Nimgaonkar, Matcheri S. Keshavan, 2012, Psychiatry Research.

Catatonic coma with profound bradycardia.

G. Fricchione, D. Goff, J. McEvoy, 2007, Psychosomatics.

Protocol : MK-0777 for the Treatment of Cognitive Impairments in Patients with Schizophrenia Treatment Units for Research of Neurocognition in Schizophrenia ( TURNS ) PI :

J. McEvoy, S. Marder, J. Mcevoy, 2022 .

A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial

J. Lieberman, J. McEvoy, K. North, 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

Standard and Higher Dose of Olanzapine in Patients With Schizophrenia or Schizoaffective Disorder: A Randomized, Double-Blind, Fixed-Dose Study

J. Lieberman, J. McEvoy, J. Volavka, 2008, Journal of clinical psychopharmacology.

Neurotrophin-3 levels in the cerebrospinal fluid of patients with schizophrenia or medical illness

J. Gilmore, J. McEvoy, L. Jarskog, 1997, Psychiatry Research.

Smoking and psychosis in patients with bipolar I disorder.

J. McEvoy, W. Wilson, Yen Kuang Yang, 2002, Comprehensive psychiatry.

Durability of Therapeutic Response With Long-Term Aripiprazole Lauroxil Treatment Following Successful Resolution of an Acute Episode of Schizophrenia.

P. Weiden, R. Risinger, J. McEvoy, 2017, The Journal of clinical psychiatry.

High-Dose Oral Ziprasidone Versus Conventional Dosing in Schizophrenia Patients With Residual Symptoms: The ZEBRAS Study

D. Goff, J. Bustillo, J. McEvoy, 2013, Journal of clinical psychopharmacology.

Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial.

T. Stroup, J. McEvoy, D. Perkins, 2003, Schizophrenia bulletin.

Criminal Justice System Involvement Among People with Schizophrenia

R. Rosenheck, J. McEvoy, R. Keefe, 2011, Community Mental Health Journal.

Case studies in neuropsychiaatry. II: Conversion pseudodementia.

J. McEvoy, C. Wells, J. Mcevoy, 1979, The Journal of clinical psychiatry.

Longitudinal consent-related abilities among research participants with schizophrenia: Results from the CATIE study

H. Gu, T. Stroup, J. McEvoy, 2011, Schizophrenia Research.

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: A randomized, double-blind trial of olanzapine versus haloperidol (American Journal of Psychiatry (2003) 160, (1396-1404))

J. Lieberman, R. Kahn, R. Gur, 2009 .

Use of psychopathology vignettes by patients with schizophrenia or schizoaffective disorder and by mental health professionals to judge patients' insight.

S. Steingard, J. McEvoy, N. Schooler, 1993, The American journal of psychiatry.

Monitoring for myocarditis during treatment initiation with clozapine

J. McEvoy, O. Freudenreich, B. Miller, 2021, Acta psychiatrica Scandinavica.

Issues in the Design and Conductance of Clinical Trials

J. McEvoy, O. Freudenreich, 2008 .

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol on treatment-resistant patients with schizophrenia and schizoaffective disorder

J. Lieberman, P. Czobor, M. Hoptman, 2001, European Neuropsychopharmacology.